Abstract
Chronic airways diseases, including asthma, COPD and cystic fibrosis, cause significant morbidity and mortality and are associated with high healthcare expenditure, in the UK and worldwide. For patients with these...
Highlights
Chronic airways diseases, including asthma, chronic obstructive pulmonary disease (COPD) and cystic fibrosis, cause significant morbidity and mortality and are associated with high healthcare expenditure, in the UK and worldwide
We provide an overview of established techniques for measuring lung function, a more detailed account of which is provided elsewhere[10], before discussing emerging techniques that may help to overcome these clinical challenges
FEV1 remains the principal means of classifying COPD severity, and it is is predictive of mortality and outcomes at a population level.[18]
Summary
Chronic obstructive airways disease (COPD) affects ~200 million people worldwide,[1] is responsible for >10% of acute NHS hospital admissions[2] and will become the third-leading cause of death by 2020.1 Asthma affects ~300 million people worldwide, causes greater overall disability in the UK than diabetes or breast cancer,[1] and places a huge burden on healthcare resources.[3]. Guidelines advocate the demonstration of obstructive spirometry (post-bronchodilation FEV1/FVC
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
